PFO
IBIO icon

Pathstone Family Office’s iBio IBIO Stock Holding History

Pathstone Family Office’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Hold
0
– – – 970
2020
Q4 		– Hold
0
– – – 1231
2020
Q2 		– Sell
-5
Closed -$3K – 836
2020
Q1 		$3K Buy
+5
New +$1.92K ﹤0.01% 661

Other funds holding IBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Pathstone Family Office's IBIO Position: Q1 2021 in Review

Pathstone Family Office held its iBio (IBIO) position steady in Q1 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #970.

Pathstone Family Office first reported a position in IBIO in Q1 2020 and has held it in 1 quarter since. The position peaked at $3K in Q1 2020. 91 funds tracked by Wall St. Rank hold IBIO as of Q1 2021.

  • Pathstone Family Office held 0 shares of iBio worth $0 as of Q1 2021.
  • Pathstone Family Office left its iBio share count unchanged in Q1 2021.
  • iBio made up ﹤0.01% of Pathstone Family Office's portfolio in Q1 2021, its #970 holding.
  • Pathstone Family Office first reported a position in iBio in Q1 2020 and has held it in 1 quarter since.
  • Pathstone Family Office's iBio position peaked at $3K in Q1 2020.
  • 91 funds tracked by Wall St. Rank held iBio as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.